Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of UCB0942 adjunctive therapy in highly drug-resistant focal epilepsy
NL-OMON50315Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padsevonil in Focal Onset Epilepsy, sponsored by UCB. Primary endpoint: Long-term safety and tolerability. Started Aug 2015; status: active, not recruiting.
02
Drugs
padsevonil
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON50315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50315.